Login Form

Lover's Peptide


Trade name: Lover's Peptide
Chemical composition: PT-141 Bremelanotide
Dosage: 10mg / vial
Unit size: 1 vial
Manufacturer: HD Laboratories

Enquire Now


Manufacturer's Description:

PT-141 Bremelanotide, PT-141 has been research tested and shown to help improve, increase ones sexual arousal in both men and woman. (Erectile dysfunction or impotence) as well as sexual dysfunction in women (sexual arousal disorder). 10mg per vial.

  • Molecular Formula: C50H68N14O10
  • Molecular Weight: 1025.2
  • CAS No. : 32780-32-8
  • Sequence: CH3CO-Nle-[Asp-His-(d)-Phe-Arg-Trp-Lys]-COOH
  • Purity (HPLC): 99% min. For RESEARCH PURPOSES ONLY

Bremelanotide or PT-141 is the generic term for a new research peptide for use in helping improve sexual dysfunction in men (erectile dysfunction or impotence) as well as helping improve sexual dysfunction in women (sexual arousal disorder).

Bremelanotide, PT-141 does not act on the vascular system like the former compounds but it is known and has been shown to help increase sexual activity in both male and female mammals. Bremelanotide PT-141 allegedly works by activating melanocortin receptors in the brain, therefore helping increase ones sexual stimulation.

PT-141, Bremelanotide is experimental and is used for the purpose of sexual arousal. It is a melanocortin based peptide that has shown effectiveness in clinical studies on both male and female rats. Male rats have shown erectile response with doses as low as 1-2 mgs whereas most female rats have shown positive results with higher doses around 2-3 mgs. While the dosage requirements tend to be higher for female rats, the observable results in female rats tend to be stronger. An example of findings among male rats is displayed below in an abstract from this Palatine study:


Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction, Int J Impot Res. 2004 Jan;16(1):51-9

Safarinejad MR., Evaluation of the safety and efficacy of Bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study., J Sex Med. 2008 Apr;5(4):887-97. Epub 2007